Tine Carmeliet
Associate – Brussels
Tel +32 2 780 2562
tine.carmeliet@allenovery.com
Tine focuses on IP law, EU Life Sciences regulatory law and privacy and EU data protection law. She advises and assists clients both in non-litigious and litigious matters in these areas.
Recent highlights of her practice include multi-jurisdictional advice on European plant and seed legislation and genetically modified organisms, clinical trials, complex cross-border data protection matters and medical devices.
Tine also conducts intellectual property litigation before the Belgian courts and advises clients on non-contentious matters in that field of expertise.
Posts by: Tine Carmeliet
- Regulatory considerations for Covid-19 next generation vaccines
- Parallel trade in the life sciences sector – recent developments
- EU Court says off-label treatments must not be considered when assessing the significant benefit criterion in orphan drugs
- Belgium - Covid-19 coronavirus: ban on at-home tests lifted
- Belgium: Covid-19: FAMHP adopts new validation procedure for serological tests
- Belgium - FAMHP supports e-PIL pilot project
- Belgium: Covid-19: use of unlicensed medicines for treatment of Covid-19
- Belgium: Covid-19 – Coronavirus: serological tests now available
- Belgium - Covid-19 coronavirus: measures affecting the life sciences sector
- Belgium - FAMHP updates guidelines on labelling and packaging of medicines
- Covid-19 coronavirus: Measures affecting the Belgium life sciences sector
- Covid-19 coronavirus: New guidance on managing clinical trials in Belgium
- EU data protection guidance on Covid-19 apps
- Belgium - New Bill on allowing access to confidential agreements between government and pharmaceutical companies
- Amendment of Belgian legislation on medicines shortages
- EMA takes specific steps to reduce possible impact of Covid-19 on pharmaceutical supply chain in EU
- Belgium - PharmaStatus: new online platform on availability of medicines
- Belgium launches International Horizon Scanning Initiative to negotiate better prices for medicines
- The Nagoya Protocol five years into play: key points of attention when working with genetic resources
- Belgium: Minister of Economy imposes maximum price for orphan drug
- Belgium introduces “linked” reimbursement procedure for personalised medicines and companion diagnostics
- Belgium: New developments point at possibly imminent changes in (online) pharmacy market
- Belgium modifies legislation regarding unavailability of medicines
- Belgian Minister of Health introduces new measures that will produce significant annual savings
- New Belgian life sciences regulations on pricing and clinical trials published
- New directive on GMP transposed into Belgian law
- Belgium launches single online portal for health data
- General Court explains the concept of environmental law in the Aarhus Convention and annuls Commission decision on products containing genetically modified soybeans
- Belgian regulator amends guidelines on labelling and packaging of human medicines
- Belgium: Digital platform for medical files to be launched
- Belgium: New proposal to cease reimbursement of costly medicinal products after patent expiry
- BeNeLuxA collaboration moves forward with launch of e-platform and two additional pilot projects
- CJEU to rule on milestone in European GMO legislation: the legal classification of mutagenesis in plant breeding
- Belgian multiannual framework agreement to streamline delivery of medicines
- Belgian Chamber of Representatives approves new innovation income system
- New innovation income system to replace royalty tax-deductible regime in Belgium as of July 2017